Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Antineoplastic Agents

All Drugs and Chemicals

Docetaxel

Tislelizumab

Cisplatin

Goserelin

Pamiparib

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Immunological

Antineoplastic Agents, Hormonal

Poly(ADP-ribose) Polymerase Inhibitors

Enzyme Inhibitors

Rezvilutamide plus ADT plus tislelizumab.

Rezvilutamide

3.6mg by intramuscular injection once 4 weeks for 24 weeks.

Goserelin Microspheres for Injection

70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).

200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).

Kaiyan Zhang, M.D.

Haichao Huang, M.D.

To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.

According to the results of the genomic profile, patients will be assigned to 4 neoadjuvant therapy (NT) groups (Queue 1 to 4): Queue 1: No targetable actionable aberration; Queue 2: Homologous recombination repair (HRR) alterations (BRCA1/2); Queue 3: Homologous recombination repair alterations (except BRCA1/2 and CDK12); Queue 4: MSI-H/dMMR, TMB≥10mut/Mb or CDK12 alterations without other HRR alterations. A following PSMA PETCT for evaluating the efficacy of NT and radical prostatectomy (RP) plus pelvic lymph node dissection (PLND) will be perform. The histopathological and survival data after RP plus PLND will also be evaluated.

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

An Exploratory Study of the Safety and Efficacy of Genomic Biomarker-guided Neoadjuvant Therapy for Locally Advanced and Oligometastatic Prostate Cancer (SEGNO)

The rate of clinical complete response (cCR) as assessed using PSMA PET/CT and mp-MRI following 20 weeks of neoadjuvant therapy

The rate of pathological minimal residual disease (defined as residual tumour 5 mm or less) as assessed on prostatectomy specimens following 24 weeks of neoadjuvant therapy

The rate of complete pathologic response (pCR) as assessed on prostatectomy specimens following 24 weeks of neoadjuvant therapy

Spots Global Cancer Trial Database for goserelin microspheres for injection